Chamber and committees

Recent advice from our statutory advisers, the Climate Change Committee (CCC), states that “sustainable bioenergy is essential for reaching net zero”. Given resource supply limitations, it must be used in those applications with the highest greenhouse gas savings (those with CO2 sequestration and/or displacement of high carbon alternatives).

The Committee recommends that the preferred use for bioenergy will be with Carbon Capture and Storage (CCS) in electricity, hydrogen and biojet applications.

Overall the Scottish Government’s aim is to see bioenergy used where it has the greatest value in reducing emissions, however this decision is also dependent on which sectors will make the best use of the bioenergy feedstocks that we can grow sustainably or produce domestically in comparison with those we may need to import.

We will publish a Bioenergy Action Plan in 2023 which will set out a strategic framework for the use of bioenergy.

In the near term our programmes which support decarbonisation of heat are promoting those technologies which have a clear long-term role.

Health Boards are required to report exit packages in their annual accounts, in line with the requirements set out in HMT’s Financial Reporting Manual. Boards’ annual accounts are publicly available on their websites.

Detail not included in the accounts or that pre dates this requirement would need to be requested from Health Boards.

The Scottish Government welcomed and supported the recommendation of the Virtual Trials National Project Board, which has the potential to deliver significant benefits for victims by reducing the traumatising impact of the court environment. The Report acknowledges that existing legislation with guidance issued by the Lord Justice General could support the further use of virtual trials. We will consider the need for legislation in a future consultation exercise.

All of the £375 million identified by the Scottish Government to provide businesses with support has now been allocated, including underspend from some of the funds, where business demand has been less than initially forecast.

I wrote to all MSPs in January to provide an update on how the initial £276 million of the £375 million Omicron business support package had been allocated.

On 10 February, I set out how a further £39.5 million of the funding package would be allocated, and on 21 Feb we announced the £80m Covid Economic Recovery Fund for local authorities to support local economies and cities recover from the pandemic.

As with all our previous business support funding, we are publishing management information on the funding paid out to businesses from this support package on a weekly basis.

The Scottish Government has committed to increasing public investment in social care by 25 per cent during the current parliamentary session. This is expected to equate to £840 million additional annual investment by the end of this parliament and will support plans for the delivery of commitments relating to social care, including the creation of a National Care Service.

These plans are currently being developed and will be considered by Ministers and by Parliament in due course, taking account responses to the National Care Service Consultation, input from stakeholders and the forthcoming Resource Spending Review to ensure that services are sustainable and best meet the needs of those who access care, and those who deliver care.

The Nightclub Closure Fund was available to nightclubs for support with meeting staffing costs for the period during which they were required to close between the 27 December and 24 January 2022. In order to qualify for this funding, businesses were required to meet eligibility as set out in guidance. This included the requirement to be trading as a nightclub as of the 20 December. In order to prove this, businesses were asked to confirm that they met five conditions including that their licence confirmed that the music exceeded 85DB after 1am. Where this was not the case businesses have been asked to provide further evidence of this.

Following notification of a decision on their applications, businesses were able to ask for this decision to be reviewed, including where this has been due to out of date information contained on licensing details.

There have been 25 reviews requested; 14 decisions overturned, 6 of these where the reason for rejection was noise levels and upon receipt of further information have been overturned. In addition 11 decision have been reviewed and upheld.

Annex F of the updated Business and Regulatory Impact Assessment (BRIA) for Scotland’s Deposit Return Scheme (DRS), which we published alongside the draft DRS Regulations on 15 December 2021, provides a sensitivity analysis of the economic case for DRS by analysing two assumptions for key scheme parameters raised by industry: a figure of 2.7bn containers per year placed on the market (compared to the 2.2bn originally modelled) and a figure of 37,000 return points (compared to the 17,000 originally modelled).

Although the original assumptions published in Table 3 of the same BRIA remain our final, and best, estimate of the costs and benefits associated with DRS, we analysed the impact on the 25-year net present value (NPV) based on these two figures suggested by industry.

Annex F, Table 2 sets out an overall NPV of £583m if the two industry assumptions are taken into account, and provides a breakdown of this figure by sector. The overall figure of £583m has been re-validated and is correct. However, a manual error was made in copying over some of the data cells in this table. The corrected figures are set out in the table below. It is important to note that the error does not affect the overall findings of the BRIA; nor does it change the overall net present value that was presented in Table 2, Annex F.

When we were notified of this error we immediately corrected it by writing to the Convener of the Net Zero, Energy, and Transport Committee. We have amended the published Business and Regulatory Impact Assessment on the Scottish Government website. To provide further reassurance following the detection of this error, all other data presented in the BRIA have been re-validated and confirmed to be correct.

People with certain neuromuscular conditions, such as motor neurone disease and multiple sclerosis, are eligible for antiviral medication The eligibility criteria for direct access to new COVID-19 treatments were developed by an independent expert working group commissioned by the UK Department of Health and Social Care and is based on detailed clinical evidence. The criteria are set out in a UK-wide clinical commissioning policy . The policy targets those higher risk individuals who have the potential to both be least likely to generate a material immune response to vaccines and be at highest risk of disease progression, hospitalisation and death.

Further information is available on NHS Inform .

In addition to the direct access arrangements described above for the most vulnerable, coronavirus oral antiviral treatments are being evaluated through a UK-wide study called PANORAMIC, run by the University of Oxford. Full details about the eligibility criteria for the study can be found at: https://www.panoramictrial.org/

The outcomes from the study will enable the NHS to fully understand how best to make use of these treatments in the future.